Etidronate does not suppress periprosthetic bone loss following cemented hip arthroplasty.
Periprosthetic bone loss after arthroplasty may threaten prosthesis survival. The current study investigated the effect of etidronate therapy on periprosthetic, contralateral hip, and spine bone mineral density (BMD) in a one-year, prospective, randomized, double-blind study on 46 patients after cemented hip arthroplasty. BMD was measured with dual-energy X-ray absorptiometry (DXA). There were no significant differences between mean BMD measurements of the etidronate and placebo groups, with the exception of the mean percent change in the spine at six months and 12 months and in Gruen zone 3 at six months; in all three cases, the etidronate group had significantly greater mean values. These findings suggest that cyclic etidronate therapy has no significant effect in suppressing periprosthetic bone loss following cemented hip arthroplasty.
Fokter
S K
SK
Department of Orthopaedic Surgery and Sports Trauma, Celje General Hospital, Oblakova 5, 3000, Celje, Slovenia. samo.fokter@guest.arnes.si
Komadina
R
R
Repse-Fokter
A
A
Yerby
S A
SA
Kocijancic
A
A
Marc
J
J
D015502:Absorptiometry, Photon; D000368:Aged; D019644:Arthroplasty, Replacement, Hip / Q000379:methods*; D001843:Bone Cements; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000494:pharmacology*; D016723:Bone Remodeling / Q000187:drug effects*; D016009:Chi-Square Distribution; D004311:Double-Blind Method; D012968:Etidronic Acid / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D011446:Prospective Studies; D018709:Statistics, Nonparametric
D001843:Bone Cements; D050071:Bone Density Conservation Agents; D012968:Etidronic Acid